Phase 1 Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Chronic Kidney Disease
NCT05042206
Chronic Disease, Chronic Kidney Disease
Seoul, South Korea
View Trial DetailsNCT Number: NCT02014792
Studies suggest that dietary omega-3 fatty acids influence the extent to which the time interval between each heart beat varies (heart rate variability; HRV). Low HRV is associated with increased risk of sudden cardiac death (SCD). The purpose of this research is to investigate the relationship between 24 hour parameters of HRV and blood omega-3 fatty acid levels in patients who have recently commenced haemodialysis.
Looking for future studies?
Notify Me40 year–80 year
All sexes
Observational
Guy's and St Thomas' Hospital, London, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6-10 wk after commencing haemodialysis treatment
Primary independent variable
Time frame: 6-10 weeks after commencing haemodialysis treatment
Primary dependent variables. Triangular index and SDNN are indicators of overall variability
Time frame: 6-10 weeks after commencing haemodialysis
Parameters of longer phase HRV: LF, VLF and SDANN
Time frame: 6-10 weeks after commencing haemodialysis
RMSSD, pNN50, HF
Time frame: 6-10 weeks after commencing haemodialysis
SDNN, Triangular index, LF, HF, VLF, SDANN, RMSSD, pNN50 calculating during nocturnal sleep-time
Time frame: 6-10 weeks after commencing haemodialysis6-10 weeks after commencing haemodialysis
Time frame: 0-6 weeks after commencing haemodialysis
Incidence of problems with dialysis access, inadequate urea reduction ratio, amount of excess oedematous fluid removed, serious adverse events
Time frame: 6-10 weeks after commencing haemodialysis
Food frequency questionnaire
Time frame: 6-10 weeks after commencing haemodialysis
Epworth Sleepiness scale and Berlin questionnaire, plus relevant medical history
Time frame: 6-10 weeks after commencing haemodialysis
Time frame: 6-10 weeks after commencing haemodialysis
Time frame: 12 months prior to commencing haemodialysis treatment
Time frame: 6-10 weeks after commencing haemodialysis
Time frame: 6-10 weeks after commencing haemodialysis
Time frame: 6-10 weeks after commencing haemodialysis
Sodium, potassium, calcium, phosphate
Looking for future studies?
Notify MeKing's College London
Other
Heart Rate Variability and Omega-3 Fatty Acid Status in Haemodialysis Patients: an Observational Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05042206
Chronic Disease, Chronic Kidney Disease
Seoul, South Korea
View Trial DetailsNCT06608212
Chronic Disease, Chronic Kidney Disease
Whippany, New Jersey, United States
View Trial DetailsNCT06131372
Body Weight, Chronic Disease
Concord, California, United States
View Trial DetailsNCT05171686
Cardiovascular Diseases, Chronic Disease
Houston, Texas, United States
View Trial Details